Formulation, evaluation and optimization of sustained release matrix tablets of captopril

Pandya, Vikram; Patel, Vandana B.; Patel, Parag R.

doi:10.4103/0975-7406.94146

Cited by 8 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of angle of repose (> 30) indicate unsatisfactory flow properties of granules (Rashid et al, 2009). A Carr's Index greater than 25 is considered an indication of poor flowability, and below 15 is of good flowability (Patel, Baria, 2009).…”

Section: Resultsmentioning

confidence: 99%

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Sarwar

Hossain

2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The present study was undertaken to develop sustained release (SR) matrix tablets of losartan potassium, an angiotensin-II antagonist for the treatment of hypertension. The tablets were prepared by direct compression method, along with Kollidon SR as release retardant polymer. The amount of losartan potassium remains fixed (100 mg) for all the three formulations whereas the amounts of Kollidon SR were 250 mg, 225 mg, and 200 mg for F-1, F-2, and F-3 respectively. The evaluation involves three stages: the micromeritic properties evaluation of granules, physical property studies of tablets, and in-vitro release kinetics studies. The USP apparatus type II was selected to perform the dissolution test, and the dissolution medium was 900 mL phosphate buffer pH 6.8. The test was carried out at 75 rpm, and the temperature was maintained at 37 o C ± 0.5 o C. The release kinetics was analyzed using several kinetics models. Higher polymeric content in the matrix decreased the release rate of drug. At lower polymeric level, the rate and extent of drug release were enhanced. All the formulations followed Higuchi release kinetics where the Regression co-efficient (R 2 ) values are 0.958, 0.944, and 0.920 for F-1, F-2, and F-3 respectively, and they exhibited diffusion dominated drug release. Statistically significant (P<0.05) differences were found among the drug release profile from different level of polymeric matrices. The release mechanism changed from non-fickian (n=0.489 for F-1) to fickian (n=0.439 and 0.429 for F-2, and F-3 respectively) as a function of decreasing the polymer concentration. The Mean Dissolution Time (MDT) values were increased with the increase in polymer concentration. Uniterms:Losartan potassium/sustained release/development. Losartan potassium/sustained release/ evaluation. Tablets/direct compression. Kollidon SR./use/release retardant.O presente estudo foi realizado para desenvolver (SR) matriz de comprimidos de liberação sustentada de losartana, um antagonista da angiotensina II, para o tratamento da hipertensão arterial. Os comprimidos foram preparados pelo método de compressão direta com Kollidon SR como polímero de liberação lenta. A quantidade de losartana potássica permanece fixa (100 mg) para todas as três formulações enquanto que as quantidades de Kollidon SR foram de 250 mg, 225 mg e 200 mg para F-1, F-2 e F-3, respectivamente. A avaliação envolve três etapas-propriedades micromeríticas dos grânulos, estudo das propriedades físicas dos comprimidos e estudos de cinética de liberação in vitro.. Selecionoou-se o aparelho USP tipo II para realizar o teste de dissolução em meio com 900 mL de tampão fosfato pH 6,8 . O teste foi realizado em 75 rpm e a temperatura foi mantida a 37 o C ± 0.5 o C. Analisou-se a cinética de liberação utilizando-se vários modelos cinéticos. Conteúdo mais alto de polímero na matriz reduziu a taxa de liberação do fármaco. Em níveis mais baixos de polímero, a taxa e a extensão de liberação do fármaco foram aumentados. Todas as formulações seguiram a cinética de libera...

show abstract

Section: Resultsmentioning

confidence: 99%

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Sarwar

Hossain

2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…One hundred tablets of batch F6 were securely packed in aluminum blister and placed in humidity chamber. [2728] There was no significance change in crushing strength and drug assay at a regular interval of 3 months during the study of 24 month as shown in Table 4. Thus, F6 formulation batch confirmed its stability.…”

Section: Resultsmentioning

confidence: 94%

Formulation and design of sustained release matrix tablets of metformin hydrochloride: Influence of hypromellose and polyacrylate polymers

Roy

Brahma

Nandi

et al. 2013

Int J App Basic Med Res

View full text Add to dashboard Cite

Aim:The current paper was an attempt to design a sustained release dosage form using various grades of hydrophilic polymers, Hypromellose (hydroxyl-propyl methylcellulose [HPMC] K15M, HPMC K100M and HPMC K200M) and Polyacrylate polymers, Eudragit RL100 and Eudragit RS100 with or without incorporating ethyl cellulose on a matrix-controlled drug delivery system of Metformin hydrochloride.Materials and Methods:Laboratory scale batches of nine tablet formulations were prepared by wet granulation technique (Low shear). Micromeritic properties of the granules were evaluated prior to compression. Tablets were characterized as crushing strength, friability, weight variation, thickness, drug content or assay and evaluated for in-vitro release pattern for 12 h using Phosphate buffer of pH 6.8 at 37 ± 0.5°C. The in-vitro release mechanism was evaluated by kinetic modeling.Results and Discussion:The results obtained revealed that HPMC K200M at a concentration of 26% in formulation (F6) was able to sustain the drug release for 12 h and followed the Higuchi pattern quasi-Fickian diffusion. With that, combined effect of HPMC K15M as an extragranular section and Eudragit RS100 displayed a significant role in drug release. Dissolution data were compared with innovator for similarity factor (f2), and exhibited an acceptable value of ≥50 Three production validation scale batches were designed based on lab scale best batch and charged for stability testing, parameters were within the limit of acceptance. There was no chemical interaction found between the drug and excipients during Fourier Transform Infrared Spectroscopy (FTIR) and Differential scanning calorimetry study.Conclusion:Hence, combinely HPMC K200M and Eudragit RS100 at a suitable concentration can effectively be used to sustain drug release.

show abstract

“…The formulated tablets were assessed for average weight, diameter, thickness, hardness, friability and drug content 8 . Invitro dissolution study, ex-vivo muco-adhesive strength and exvivo residence time were also evaluated [9][10] .…”

Section: Evaluation Of Physicochemical Properties Of Matrix Tabletsmentioning

confidence: 99%

Formulation Development and Evaluation of Bio-Adhesive Carbopol 974p Nf Polymer Matrix Based Sustained Release Gliclazide Tablet

Anisuzzman¹,

Islam²,

Rashid³

et al. 2017

Int. Res. J. Pharm.

View full text Add to dashboard Cite

The aim of the present study was to develop a sustained release bio-adhesive matrix based Gliclazide tablet to match the in-vitro and ex-vivo experimental profile, and can be used to the treatment of Type II Diabetes Mellitus. It will be expected that single Gliclazide tablet reduce glycosylated hemoglobin and overcoming individual large fluctuation of oral bioavailability. Eleven types of tablets were formulated by wet granulation technique which contains 30 mg of Gliclazide and different concentrations of diverse bio-adhesive polymers which conforming to the USP/BP monograph. The prepared tablets were evaluated for their physicochemical parameters, bio-adhesive behavior and also in-vitro release pattern and ex-vivo residence time. Formulated F-6 tablet (300 mg) contains 30 mg Gliclazide, 90 mg Carbopol 974P NF, 155 mg Lactose, 15 mg Povidone, 5 mg Magnesium Stearate and 5 mg Talc. Carbopol based F-6 tablets showed highest significance adherence (164.1 gm) property and also exhibited greater than 300 minutes ex-vivo residence time. In-vitro release pattern of F-6 formulation was 44.74% (Mean Dissolution Time 52.86 hrs which was studied for 8 hours in phosphate buffer media at pH 7.4. Different kinetic models including zero order, first order, Higuchi and Korsmeyer pattern were applied to evaluate drug release behavior. Zero order and Korsmeyer pattern indicated most appropriate model for describing the release profile of F-6 formulation. The drug release mechanism was consequently found to be diffusion, swelling and erosion. The results point out that Carbopol 974P NF bio-adhesive matrix Gliclazide tablets have marked sustained release properties.

show abstract

Formulation, evaluation and optimization of sustained release matrix tablets of captopril

Cited by 8 publications

References 5 publications

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Development and evaluation of sustained release losartan potassium matrix tablet using kollidon SR as release retardant

Formulation and design of sustained release matrix tablets of metformin hydrochloride: Influence of hypromellose and polyacrylate polymers

Formulation Development and Evaluation of Bio-Adhesive Carbopol 974p Nf Polymer Matrix Based Sustained Release Gliclazide Tablet

Contact Info

Product

Resources

About